epirubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 217 Diseases   230 Trials   230 Trials   3979 News 


«12...1819202122232425262728...5051»
  • ||||||||||  Review, Journal:  Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations. (Pubmed Central) -  Apr 10, 2021   
    Four main strategies comprising PEGylation, surface charging, targeting, and stimuli responsiveness can be deployed to improve the liposomal and polymeric nanoformulations that can efficiently deliver common anthracylcines namely daunorubicin (DAU), doxorubicin (DOX), idarubicin (IDA), and epirubicin (EPI). Herein, the advances and challenges pertaining to the formulations of these anticancer drugs via liposomal and polymeric nanoformulations, are discussed.
  • ||||||||||  methotrexate / Generic mfg., paclitaxel / Generic mfg.
    Biomarker, Journal:  The Role of CXCL13 and CXCL9 in Early Breast Cancer. (Pubmed Central) -  Mar 30, 2021   
    Chemokines can be associated with breast cancer subtype and outcome. These data should be evaluated prospectively.
  • ||||||||||  epirubicin / Generic mfg.
    Journal:  Supercritically dried superparamagnetic mesoporous silica nanoparticles for cancer theranostics. (Pubmed Central) -  Mar 30, 2021   
    The three types of nanoparticles exhibited loading contents of epirubicin of ~3% and drug release percentages of 19% for IO-OAm/mSiO, 24% for IO-APTES/mSiO and 31% for IO/SiO/mSiO. The cytotoxicity of drug-loaded and non-loaded most promising nanoparticles was assessed, showing high potential of these platforms for application as anticancer drug carriers.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) -  Mar 26, 2021   
    P2,  N=242, Completed, 
    Registration URL: http://www.clinicaltrials.gov; Unique identifier: NCT02125344. Active, not recruiting --> Completed | N=400 --> 242 | Trial completion date: Jul 2020 --> Oct 2020 | Trial primary completion date: Apr 2020 --> Oct 2020
  • ||||||||||  daunorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
    Journal:  Profound Nanoscale Structural and Biomechanical Changes in DNA Helix upon Treatment with Anthracycline Drugs. (Pubmed Central) -  Mar 26, 2021   
    On the other hand, EPI has the lowest preference for GC-rich dsDNA. Moreover, we demonstrated that the nanoscale perturbations in dsDNA topology are reflected by changes in the microscale properties of the cell, as even short exposition to doxorubicin resulted in an increase in nuclei stiffness, which can be due to aberration of the chromatin organization, upon intercalation of doxorubicin molecules.
  • ||||||||||  epirubicin / Generic mfg.
    Clinical, P3 data, Journal:  Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. (Pubmed Central) -  Mar 20, 2021   
    Our study demonstrates that novel lnc005620 promotes TNBC progression and chemoresistance to epirubicin via integrin β1 both in vitro and in vivo and provides a promising therapeutic target for TNBC patients in terms of enhancing the benefits of epirubicin treatment. Updated results from the MIG-1 study are numerically in favour of dose-dense chemotherapy, and suggest a long-term benefit of this approach in high-risk early breast cancer patients.
  • ||||||||||  zoledronic acid / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
    [VIRTUAL] LIFE THREATENING MALIGNANT HYPERCALCEMIA IN BREAST CANCER: CAN THE NEPHROLOGIST CHANGE THE PATIENT DESTINY? (Mini-Orals Hall) -  Mar 19, 2021 - Abstract #ERAEDTA2021ERA_EDTA_1410;    
    Malignant hypercalcemia is a life-threatening complication in advanced malignancies. Our case report highlights the key role of the nephrologist in treating a complex and fragile oncologic patient, achieving the full correction of several severe renal disorders, hemodialysis avoidance and survival improvement.
  • ||||||||||  Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
    Trial completion, Trial completion date, Metastases:  TavIx: Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (clinicaltrials.gov) -  Mar 16, 2021   
    P3,  N=762, Completed, 
    Although dose-dense chemotherapy was associated with a significant survival improvement in high-risk breast cancer patients, its benefit appeared to be smaller (if any) in patients with HER2-positive disease who received adjuvant trastuzumab. Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> Sep 2020
  • ||||||||||  epirubicin / Generic mfg.
    [VIRTUAL] ROLE OF NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED CARCINOMA STOMACH (DDW Virtual) -  Mar 15, 2021 - Abstract #DDW2021DDW_2530;    
    In view of high progression rates, patient selection is required when NACT is planned in carcinoma stomach which is surgically resectable at presentation. We await survival analysis to further validate the role of NACT.
  • ||||||||||  ifosfamide / Generic mfg., epirubicin / Generic mfg.
    [VIRTUAL] Patient-derived 3D sarcoma model - robust system for sarcoma research and personalized therapy selection () -  Mar 11, 2021 - Abstract #AACR2021AACR_2232;    
    Ifosfamide did not show any significant effect, probably due to the requirement for its activation by liver enzymes...Trabectedin is currently only approved as a second line treatment for liposarcoma and leiomyosarcoma by the FDA...We hope that further development of our collection will allow us to cover the whole spectrum of sarcomas, generating much needed tool for investigating soft-tissue tumors, and allowing for successful development of a targeted therapeutic approach. Overall, our results indicate, that sarcoma PD3D cultures are a viable option for personalized medicine approach, previously unavailable for sarcoma patients.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    [VIRTUAL] Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial (Channel 1) -  Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_143;    
    P2
    Patients with stage IIA to III HER2-positive breast cancer and a left ventricular ejection fraction (LVEF) ≥55% were allocated per physician's choice to cohort A (dose-dense doxorubicin/cyclophosphamide every 2 weeks [q2w] x 4 → paclitaxel q1w x 12) or cohort B (5-fluorouracil, epirubicin, cyclophosphamide q3w x 4 → docetaxel q3w x 4).  The final analysis of BERENICE showed sustained cardiac safety and favorable long-term efficacy outcomes, further supporting neoadjuvant/adjuvant PH with standard anthracycline-containing therapies in patients with early stage HER2-positive breast cancer.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    [VIRTUAL] Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study (Channel 2) -  Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_132;    
    P2
     The final analysis of BERENICE showed sustained cardiac safety and favorable long-term efficacy outcomes, further supporting neoadjuvant/adjuvant PH with standard anthracycline-containing therapies in patients with early stage HER2-positive breast cancer. Postmenopausal women with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III BC, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks (LETPAL), or to FEC100 (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) x3 21-day courses followed by docetaxel 100 mg/m2 x3 21-day courses (CT)... Despite its small size, NeoPAL suggests that a neoadjuvant LETPAL strategy, together with selected postoperative administration of chemotherapy, may spare chemotherapy in some pts with LBC while allowing good long-term outcomes.
  • ||||||||||  docetaxel / Generic mfg., epirubicin / Generic mfg.
    Trial completion date, Tumor cell:  Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow (clinicaltrials.gov) -  Mar 8, 2021   
    P2,  N=1128, Active, not recruiting, 
    Postmenopausal women with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III BC, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks (LETPAL), or to FEC100 (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) x3 21-day courses followed by docetaxel 100 mg/m2 x3 21-day courses (CT)... Despite its small size, NeoPAL suggests that a neoadjuvant LETPAL strategy, together with selected postoperative administration of chemotherapy, may spare chemotherapy in some pts with LBC while allowing good long-term outcomes. Trial completion date: Dec 2019 --> Dec 2022
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg., idarubicin hydrochloride / Generic mfg.
    Journal:  Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis. (Pubmed Central) -  Mar 3, 2021   
    Our findings indicate that echinacoside and epirubicin target mycobacterial DNA gyrase, inhibit its catalytic cycle, and retard mycobacterium growth. Further, these compounds exhibit potential scaffolds for optimizing novel anti-mycobacterial agents that can act on drug-resistant strains.